Merck Patent Gmbh

Merck Sharp + Dohme Corp.

University of Virginia

Aerie Pharmaceuticals, Inc.

Trevena, Inc.

Avista Pharma Solutions, Inc.

Seynexis, Inc.

Brian H Heasley

Thomas E Richardson

Andreas Goutopoulos

Henry Yu

Pandi Bharathi

Jiezhen Li

Frank Stieber

Brian Lewis Hodous

Ruoxi Lan

Bayard R Huck

Xiaoling Chen

Yufang Xiao

Srinivasa R Karra

Hui Qiu

Reinaldo Jones

Lesley Liu-Bujalski

Robert J Foglesong

Amanda E Sutton

Matthew G Jenks

Harold George Vandeveer

David Perrey

Mitchell Anthony deLong

Timothy L MacDonald

Allen E Eckhardt

Mark L Greenlee

Robert R Wilkening

Kevin R Lynch

Dongfang Meng

Jason Daniel Speake

Kenneth J Wildonger

Joe B Perales

James M Apgar

Marcos Sznaidman

Dann LeRoy Parker, Jr

Robert H Oakley

Michael Robert Peel

Donald M Sperbeck

Ahmed Mamai

Keqiang Li

Gregory Pacofsky

Christine Hudson

Jeffrey A Adams

Jeffrey David Yingling

Kurt S Van Horn

Jennifer Wilent

Patrick J Koestler

Bakela Nare

Cisco Bee

Paresma R Patel

Byappanahally N Narasinga Rao

Claire Louise Murray

Kingsley Nelson

Mitchell A Delong

Marcos L Sznaidman

Jeffrey D Yingling

Reinaldo C Jones

The present embodiments are directed, in part, to processes and compositions that can, for example, be used in the preparation compounds of Formula (I), or a pharmaceutically acceptable salts thereof.

Compounds and methods of preparing compounds S1P1 modulators

The present invention relates to single enantiomer isothiazoline compounds of formula (I): and methods of synthesizing the compounds. The compounds are useful for combating or controlling invertebrate pests, in particular arthropod pests and nematodes. The invention also relates to a method for controlling invertebrate pests by using these compounds and to veterinary compositions comprising said compounds.

Single enantiomer antiparasitic compounds

Novel benzamide derivatives of formula (I) wherein W, W, Rto Rand X have the meaning according to the claims, are positive allosteric modulators of the FSH receptor, and can be employed, inter alia, for the treatment of fertility disorders.

Benzamide derivatives as modulators of the follicle stimulating hormone

Novel benzamide derivatives of formula (I) wherein W, W, Rto R, R, X and Y have the meaning according to the claims, are positive allosteric modulators of the FSH receptor, and can be employed, inter alia, for the treatment of fertility disorders.

Benzamides

The invention provides novel substituted amino azaheterocyclic carboxamide compounds according to Formula (I), their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.

Amino azaheterocyclic carboxamides

Novel derivatives of enfumafungin are disclosed herein, along with their pharmaceutically acceptable salts, hydrates and prodrugs. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and methods of using such compounds as antifungal agents and/or inhibitors of (1,3)-&#x3b2;-D-glucan synthase. The disclosed compounds, their pharmaceutically acceptable salts, hydrates and prodrugs, as well as compositions comprising such compounds, salts, hydrates and prodrugs, are useful for treating and/or preventing fungal infections and associated diseases and conditions.

Antifungal agents

The present invention is directed to compositions comprising lysophosphatidic acid analogs and methods of using such analogs as agonist or antagonists of LPA receptor activity. In addition the invention is directed to LPA receptor agonists that vary in the degree of selectivity at individual LPA receptors (i.e. LPA1, LPA2 and LPA3). More particularly the present invention is directed to LPA analogs wherein the glycerol is replaced with ethanolamine and a variety of substitutions have been linked at the second carbon atom.

Lysophosphatidic acid receptor selective antagonists

Isoquinoline compounds with G are provided that influence, inhibit or reduce the action of a G-protein receptor kinase. Pharmaceutical compositions including therapeutically effective amounts of the isoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, osteoporosis and glaucoma are also provided.

Isoquinoline compounds

Growing community of inventors

Wake Forest, NC, United States of America

Brian H Heasley